Peloton will offer safety guard for recalled Tread+ treadmill

Peloton will offer safety guard for recalled Tread+ treadmill


Maggie Lu uses a Peloton Tread+ treadmill during CES 2018 at the Las Vegas Convention Center, January 11, 2018.

Ethan Miller | Getty Images

Peloton said Thursday it would release a rear safety guard for its Tread+ treadmill, working with the U.S. Consumer Product Safety Commission.

The stock rose more than 1% on the news.

The Tread+ treadmill has been at the heart of safety concerns surrounding Peloton in recent years. Sales for the treadmill have been halted since a young child died under a Tread+ treadmill in 2021.

Since the recall, there have been 279 more reported incidents and 61 reports of injuries, Peloton and CPSC said in a joint statement.

The safety guard will be offered free of charge to people who own a Tread+ treadmill, the company said in a release.

Customers can register in advance to receive the guard. It is still being manufactured and is expected to be available in the fall.

Following the 2021 recall, Peloton told Tread+ treadmill owners to stop using the product.

The new guard has a breakaway design that moves away from the treadmill when it touches an object, which turns off power and decelerates the belt. It aims to eliminate the potential for entrapment near the treadmill’s rear, which is primarily what caused incidents in the past.

“As a brand dedicated to empowering Members on their fitness journey, Peloton remains committed to ensuring they have access to our world-class fitness experiences in the safest way possible,” the company said.

In addition to the Tread+ treadmill’s woes, other safety concerns have plagued Peloton in recent years.

Amid the mounting concerns, the company changed its stance on recalls in recent weeks.

Last week, when the CPSC recalled 2.2 million Peloton bikes over safety concerns, Peloton cooperated, saying it was “important to proactively engage the CPSC to address this issue and to work swiftly and cooperatively to identify a remedy.”

A part defect on model number PL01 bikes led to 12 reported injuries, including one wrist fracture, according to an internal Peloton memo.

Previously, the company was slow to cooperate with officials and expressed disagreement over potential flaws. Peloton said it took action, despite the relatively small number of affected bikes, because it was a “member-first company,” according to the internal memo.

Earlier this month, the company posted a wider-than-expected loss for its fiscal third quarter while forecasting its first-ever decline in subscribers.



Source

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored
Business

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored

In this photo illustration Hantavirus samples are seen in Ankara, Turkiye on May 6, 2026. Arman Onal | Anadolu | Getty Images The U.S. Centers for Disease Control and Prevention said there are no hantavirus cases in the country as of Thursday, as it monitors 41 people for the virus. The agency said the risk […]

Read More
These three artworks could sell for 0 million each next week as May auctions begin
Business

These three artworks could sell for $100 million each next week as May auctions begin

A large-scale Jackson Pollock drip painting titled, “Number 7A, 1948.” Crystal Lau | CNBC A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Nearly $2 billion worth of art will come up […]

Read More
Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data
Business

Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen plans to advance an experimental drug for Alzheimer’s disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses. […]

Read More